BioNTech (Pfizer) says in its annual report to the US Securities and Exchange Commission that the efficacy of its current mRNA Corona vaccine may not be sufficient for permanent regulatory approval.https://t.co/mMkjvgFjVn pic.twitter.com/IH2IPltQwq

— MKGRN (@MKGRN14) April 25, 2022